Antileukemic effects of topoisomerase I inhibitors mediated by de-SUMOylase SENP1

Niu, Qun; Hou, Wanxin; Yan, Yinjie; Sun, Shuzhang; Lin, Yanyan; Fang, Haiping; Ma, Chunshuang; Cheng, Yixuan; Xu, Yan; Ding, Ming; Wang, Shuxuan; Cui, Zhiyan; Chen, Yao; Li, Hegen; Li, Hui; Xiao, Ning

doi:10.1016/j.bbadis.2022.166492

Cited by 6 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a novel inhibitor of global SUMOylation, topotecan has demonstrated remarkable anticancer, anti-inflammatory, and neuroprotective effects(Bernstock et al 2017 ; Mo et al 2002 ). Additionally, some research indicated that topotecan may induce SENP1 reduction, producing antileukemic effects(Niu et al 2022 ). Besides, SUMO E1 activator drug N106 also serve as a potential therapeutic strategy for treatment of heart failure by increasing SUMOylation of SERCA2a(Kho et al 2015 ).…”

Section: Directions For Future Researchmentioning

confidence: 99%

The emerging roles of SUMOylation in pulmonary diseases

Zheng,

Wang,

Zhang

et al. 2023

Mol Med

View full text Add to dashboard Cite

Small ubiquitin-like modifier mediated modification (SUMOylation) is a critical post-translational modification that has a broad spectrum of biological functions, including genome replication and repair, transcriptional regulation, protein stability, and cell cycle progression. Perturbation or deregulation of a SUMOylation and deSUMOylation status has emerged as a new pathophysiological feature of lung diseases. In this review, we highlighted the link between SUMO pathway and lung diseases, especially the sumoylated substrate such as C/EBPα in bronchopulmonary dysplasia (BDP), PPARγ in pneumonia, TFII-I in asthma, HDAC2 in chronic obstructive pulmonary disease (COPD), KLF15 in hypoxic pulmonary hypertension (HPH), SMAD3 in idiopathic pulmonary fibrosis (IPF), and YTHDF2 in cancer. By exploring the impact of SUMOylation in pulmonary diseases, we intend to shed light on its potential to inspire the development of innovative diagnostic and therapeutic strategies, holding promise for improving patient outcomes and overall respiratory health.

show abstract

Section: Directions For Future Researchmentioning

confidence: 99%

The emerging roles of SUMOylation in pulmonary diseases

Zheng,

Wang,

Zhang

et al. 2023

Mol Med

View full text Add to dashboard Cite

show abstract

“…Overexpressed SENP1 is found in leukemia, multiple myeloma (MM) and mantle cell lymphoma ( Ohbayashi et al, 2008 ; Xu et al, 2015 ; Wang FF. et al, 2016 ; Zhang et al, 2021 ; Niu et al, 2022 ; Liu J. et al, 2023 ). In conclusion, SENP1 might play an oncogenic role not only in solid tumor, but also in malignant tumor, which deserves further exploring about the specific mechanism.…”

Section: Introductionmentioning

confidence: 97%

“…In acute lymphoblastic leukemia (ALL), Topotecan was found to inhibit cells proliferation through SENP1 reduction. 7-ethylcamptothecin (7E-CPT), another camptothecin derivative, can downregulate SENP1 mRNA and protein levels, which suppresses ALL cells proliferation and induced apoptosis ( Niu et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Emerging role of SENP1 in tumorigenesis and cancer therapy

Lin,

Zhang,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Acting as a cysteine protease, small ubiquitin-like modifier (SUMO)/sentrin-specific protease1 (SENP1) involved in multiple physiological and pathological processes through processing the precursor SUMO protein into mature form and deSUMOylating target protein. It has been reported that SENP1 is highly expressed and plays a carcinogenic role in various cancers. In this paper, we mainly explore the function and mechanism of SENP1 in tumor cell proliferation, apoptosis, invasion, metastasis, stemness, angiogenesis, metabolism and drug resistance. Furthermore, the research progress of SENP1 inhibitors for cancer treatment is introduced. This study aims to provide theoretical references for cancer therapy by targeting SENP1.

show abstract

ACLY-β-catenin axis modulates hepatoblastoma cell proliferation

Lin

Fang

et al. 2023

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Antileukemic effects of topoisomerase I inhibitors mediated by de-SUMOylase SENP1

Cited by 6 publications

References 33 publications

The emerging roles of SUMOylation in pulmonary diseases

The emerging roles of SUMOylation in pulmonary diseases

Emerging role of SENP1 in tumorigenesis and cancer therapy

ACLY-β-catenin axis modulates hepatoblastoma cell proliferation

Contact Info

Product

Resources

About